Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals

JAMA. 2022 Jan 18;327(3):279-281. doi: 10.1001/jama.2021.21921.

Authors

Brian Grunau¹, David M Goldfarb², Michael Asamoah-Boaheng³, Liam Golding⁴, Tracy L Kirkham⁵, Paul A Demers⁵, Pascal M Lavoie⁶

Affiliations

¹ Department of Emergency Medicine, University of British Columbia, Vancouver, Canada.
² Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
³ Faculty of Medicine, Memorial University of Newfoundland, St John's, Canada.
⁴ Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.
⁵ Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
⁶ Department of Pediatrics, University of British Columbia, Vancouver, Canada.

Abstract

This study investigates the immunogenicity of extended mRNA vaccine dosing intervals.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

2019-nCoV Vaccine mRNA-1273 / administration & dosage*
2019-nCoV Vaccine mRNA-1273 / immunology*
Adult
Allied Health Personnel
Angiotensin-Converting Enzyme 2 / immunology
Antibodies, Neutralizing / blood
BNT162 Vaccine / administration & dosage*
BNT162 Vaccine / immunology*
Canada
Female
Humans
Immunization Schedule*
Immunoglobulin G / blood
Male
SARS-CoV-2 / immunology*
Spike Glycoprotein, Coronavirus / immunology

Substances

Antibodies, Neutralizing
Immunoglobulin G
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
ACE2 protein, human
Angiotensin-Converting Enzyme 2
2019-nCoV Vaccine mRNA-1273
BNT162 Vaccine

Supplementary concepts

SARS-CoV-2 variants